Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures

Haemonetics Corporation (NYSE: HAE) has received FDA approval for its PerQseal Elite vascular closure system, designed for large-bore arterial procedures. This approval enhances Haemonetics' product offerings in the large-bore closure device market, particularly for structural heart and endovascular procedures. The approval follows Haemonetics' acquisition of Vivasure Medical Limited in January 2026.